Zobrazeno 1 - 10
of 19
pro vyhledávání: '"PHILIPPE HUOT-MARCHAND"'
Autor:
Michael P. Cooreman, Javed Butler, Robert P. Giugliano, Faiez Zannad, Lucile Dzen, Philippe Huot-Marchand, Martine Baudin, Daniel R. Beard, Jean-Louis Junien, Pierre Broqua, Manal F. Abdelmalek, Sven M. Francque
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health (CMH) and cardiovascular events as major mortality cause. NATIVE trial
Externí odkaz:
https://doaj.org/article/a8349f7dd9df4b16ac7569db5e4e8c59
Autor:
Bernard Combe, Rene-Marc Flipo, Alain Saraux, Francis Fagnani, Jacques Massol, Gabrielle Cukierman, Jean-Michel Joubert, Philippe Huot-Marchand
Publikováno v:
RMD Open, Vol 6, Iss 1 (2020)
ObjectiveTo evaluate the performance of clinical criteria for predicting late treatment failure in patients with early non-response to certolizumab pegol (CZP).MethodsA protocol-specified analysis of interim data from ECLAIR, a 3-year longitudinal, p
Externí odkaz:
https://doaj.org/article/a7c0fd1c17fd440db3df7951cfa3bfb5
Autor:
Nathalie Guffon, Pratima Chowdary, Elisa Leão Teles, Derralynn Hughes, Julia B. Hennermann, Philippe Huot‐Marchand, Elodie Faudot‐Vernier, Olivier Lacombe, Anne Fiquet, Marie‐Paule Richard, Jean‐Louis Abitbol, Mireille Tallandier, Christian J. Hendriksz
Publikováno v:
Journal of Inherited Metabolic Disease. 45:340-352
Mucopolysaccharidosis (MPS) disorders are a group of rare, progressive lysosomal storage diseases characterized by the accumulation of glycosaminoglycans (GAGs) and classified according to the deficient enzyme. Enzyme replacement therapy (ERT) of MPS
Autor:
MICHAEL P. COOREMAN, SVEN FRANCQUE, LUCILE DZEN, PHILIPPE HUOT-MARCHAND, JEAN L. JUNIEN, PIERRE BROQUA, MANAL F. ABDELMALEK
Publikováno v:
Diabetes. 71
Lanifibranor therapy resulted in both NASH resolution and fibrosis reduction in the phase 2b NATIVE study in patients with non-cirrhotic NASH, compared to placebo. PPAR signaling is involved in common pathways of NASH and type 2 diabetes (T2D) . We e
Autor:
Michael Cooreman, Sven Francque, Martine Baudin, Philippe Huot-Marchand, Lucile Dzen, Jean-Louis Junien, Pierre Broqua, Manal Abdelmalek
Publikováno v:
Journal of Hepatology. 77:S722-S723
Autor:
Michael Cooreman, Manal Abdelmalek, Martine Baudin, Philippe Huot-Marchand, Lucile Dzen, Céline Fournier, Jean-Louis Junien, Pierre Broqua, Sven Francque
Publikováno v:
Journal of Hepatology. 77:S722
Autor:
Jerome Boursier, Hugo Herve, Clémence M Canivet, Marine Roux, Pierre Broqua, Michael Cooreman, Jean-Louis Junien, Jean Louis Abitbol, Philippe Huot-Marchand, Lucile Dzen, Sanjaykanumar Patel
Publikováno v:
Journal of Hepatology. 77:S715
Autor:
Jean-Michel Joubert, Alain Saraux, Francis Fagnani, René-Marc Flipo, G. Cukierman, Philippe Huot-Marchand, Jacques Massol, Bernard Combe
Publikováno v:
RMD Open : Rheumatic & Musculoskeletal Diseases
RMD Open : Rheumatic & Musculoskeletal Diseases, 2020, 6 (1), pp.e000991. ⟨10.1136/rmdopen-2019-000991⟩
RMD Open : Rheumatic & Musculoskeletal Diseases, EULAR ; BMJ, 2020, 6 (1), pp.e000991. ⟨10.1136/rmdopen-2019-000991⟩
RMD Open, Vol 6, Iss 1 (2020)
RMD Open
RMD Open : Rheumatic & Musculoskeletal Diseases, 2020, 6 (1), pp.e000991. ⟨10.1136/rmdopen-2019-000991⟩
RMD Open : Rheumatic & Musculoskeletal Diseases, EULAR ; BMJ, 2020, 6 (1), pp.e000991. ⟨10.1136/rmdopen-2019-000991⟩
RMD Open, Vol 6, Iss 1 (2020)
RMD Open
ObjectiveTo evaluate the performance of clinical criteria for predicting late treatment failure in patients with early non-response to certolizumab pegol (CZP).MethodsA protocol-specified analysis of interim data from ECLAIR, a 3-year longitudinal, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16b37941b130076736a88cd5ee48d5ac
https://hal.umontpellier.fr/hal-03462274/document
https://hal.umontpellier.fr/hal-03462274/document
Publikováno v:
Pharmaceutical Medicine. 32:343-352
To support a positive benefit/risk profile for crizotinib, additional risk minimization measures (RMMs) included a patient information brochure (PIB) and a therapeutic management guide (TMG) to inform patients and physicians in Europe about the risks
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.